Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 15/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29516344 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EKMT2ASIRT1SIRT2 | |
| SCHEMBL26938739 | 0.89 | KMT2A (0.47) | ALDH1A1KDM4EKMT2ASIRT1L3MBTL1 | |
| SCHEMBL26938829 | 0.78 | SIRT1 (0.65) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24378118 | 0.78 | SIRT1 (0.65) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24378125 | 0.78 | SIRT1 (0.65) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24377955 | 0.78 | SIRT1 (0.52) | KMT2ASIRT1SIRT2SIRT3 | |
| SCHEMBL29516212 | 0.78 | SIRT1 (0.52) | KMT2ASIRT1SIRT2SIRT3 | |
| SCHEMBL24378019 | 0.74 | SIRT1 (0.48) | SIRT1SIRT2SIRT3 | |
| SCHEMBL24378122 | 0.73 | TP53 (0.49) | ALDH1A1KMT2ASIRT1L3MBTL1 | |
| SCHEMBL29516214 | 0.73 | SIRT1 (0.49) | SIRT1SIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570620-B2 | Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570620-B2 | Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer | CSNK1A1L, CKMT1A; CKMT1B, KHK | ALDH1A1 1714/4885KDM4E 262/4885KMT2A 476/4885 |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | ALDH1A1 924/4885KDM4E 619/4885KMT2A 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.